» Articles » PMID: 23021876

The Influence of Infliximab and Adalimumab on the Expression of Apoptosis-related Proteins in Lamina Propria Mononuclear Cells and Enterocytes in Crohn's Disease - an Immunohistochemical Study

Overview
Date 2012 Oct 2
PMID 23021876
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: The aim of this study was to assess the influence of anti-TNF agents on the expression of apoptosis-related proteins in Crohn's disease (CD) patients.

Methods: The clinical, biochemical and endoscopic activity of CD was assessed with the use of tissue sampling before the initiation of therapy and after induction doses of infliximab and adalimumab. Additionally, the immunohistochemical expression of active caspase 3, TNFR1, Fas, Bcl-2, Bax, CD4 and CD8 proteins was estimated. Patients achieving deep remission were considered as responders.

Results: Of the 35 patients qualified for the study, 60% achieved deep remission. In those patients, a significant decrease in the number of CD4 and CD8 positive cells was noted. Also observed was a significant increase in the expression of active caspase 3 in lamina propria mononuclear cells, which correlated with an increase of the pro-apoptotic Bax/Bcl-2 ratio. No change in Fas and TNFR1 expression was observed in those cells. Moreover, there was a significant decrease in active caspase 3 expression in enterocytes, observed independently of the Bax/Bcl-2 ratio. This correlated with a change in TNFR1 expression. No significant changes in the expression of the investigated proteins were noted in non-responders group.

Conclusions: The efficacy of anti-TNF antibodies is, at least partly, dependent on apoptosis modulation. In lamina propria mononuclear cells, the increase of apoptosis is probably the result of the induction of the intrinsic pathway mediated by Bcl-2 family proteins. In enterocytes - the decrease of apoptosis is mediated by the extrinsic pathway, probably via TNFR1.

Citing Articles

Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn's disease patients.

Lykowska-Szuber L, Walczak M, Stawczyk-Eder K, Krela-Kazmierczak I, Eder P, Zakerska-Banaszak O J Appl Genet. 2023; 64(4):759-768.

PMID: 37658984 PMC: 10632275. DOI: 10.1007/s13353-023-00783-7.


Shenling Baizhu Powder Alleviates TNBS-Induced Colitis in Rats by Improving Intestinal Epithelial Permeability and Inhibiting Inflammation Through the TLR5/MyD88/NF-κB Pathway.

Rao K, Qin S, Yang Y, Zhan K, Wu H, Zheng H Front Pharmacol. 2022; 13:883918.

PMID: 35571126 PMC: 9096158. DOI: 10.3389/fphar.2022.883918.


The Emerging Role of Bile Acids in the Pathogenesis of Inflammatory Bowel Disease.

Thomas J, Modos D, Rushbrook S, Powell N, Korcsmaros T Front Immunol. 2022; 13:829525.

PMID: 35185922 PMC: 8850271. DOI: 10.3389/fimmu.2022.829525.


Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease.

Gareb B, Otten A, Frijlink H, Dijkstra G, Kosterink J Pharmaceutics. 2020; 12(6).

PMID: 32545207 PMC: 7356880. DOI: 10.3390/pharmaceutics12060539.


Modulator role of infliximab and methotrexate through the transient receptor potential melastatin 2 (TRPM2) channel in neutrophils of patients with rheumatoid arthritis: a pilot study.

Dogru A, Naziroglu M, Cig B Arch Med Sci. 2019; 15(6):1415-1424.

PMID: 31749869 PMC: 6855169. DOI: 10.5114/aoms.2018.79485.